Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SuperGen, a developer of novel cancer therapeutics, has acquired UK based biotechnology firm Astex Therapeutics for $25m.
Subscribe to our email newsletter
Following the acquisition, Astex has become a wholly owned subsidiary of SuperGen.
SuperGen plans to re-brand Astex Therapeutics as Astex Pharmaceuticals in the third quarter of 2011.
The combined company’s clinical pipeline includes seven drugs in development, four of which are currently in or entering into Phase II clinical trials and three of which are currently partnered with large pharmaceutical companies.